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ABSTRACT
Background
The differential pathophysiologic mechanisms that trigger and maintain the two forms of
inflammatory bowel disease (IBD), Crohn disease (CD), and ulcerative colitis (UC) are only
partially understood. cDNA microarrays can be used to decipher gene regulation events at a
genome-wide level and to identify novel unknown genes that might be involved in
perpetuating inflammatory disease progression.
Methods and Findings
High-density cDNA microarrays representing 33,792 UniGene clusters were prepared.
Biopsies were taken from the sigmoid colon of normal controls (n ¼ 11), CD patients (n ¼
10) and UC patients (n¼10).
33P-radiolabeled cDNA from purified poly(A)
þ RNA extracted from
biopsies (unpooled) was hybridized to the arrays. We identified 500 and 272 transcripts
differentially regulated in CD and UC, respectively. Interesting hits were independently verified
by real-time PCR in a second sample of 100 individuals, and immunohistochemistry was used
for exemplary localization. The main findings point to novel molecules important in abnormal
immune regulation and the highly disturbed cell biology of colonic epithelial cells in IBD
pathogenesis, e.g., CYLD (cylindromatosis, turban tumor syndrome) and CDH11 (cadherin 11, type
2). By the nature of the array setup, many of the genes identified were to our knowledge
previously uncharacterized, and prediction of the putative function of a subsection of these
genes indicate that some could be involved in early events in disease pathophysiology.
Conclusion
A comprehensive set of candidate genes not previously associated with IBD was revealed,
which underlines the polygenic and complex nature of the disease. It points out substantial
differences in pathophysiology between CD and UC. The multiple unknown genes identified
may stimulate new research in the fields of barrier mechanisms and cell signalling in the
context of IBD, and ultimately new therapeutic approaches.
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The two main forms of inﬂammatory bowel disease (IBD),
Crohn disease (CD) and ulcerative colitis (UC), are both
characterised by an aberrant immune response of the
intestinal mucosa. The current understanding of disease
pathogenesis suggests a complex interplay of multiple
environmental and genetic factors [1]. Although clinical,
endoscopic, histopathologic, and radiologic criteria exist to
distinguish CD from UC, considerable overlap is found in
clinical criteria, understanding of pathophysiology, and
therapy [2]. The enormous complexity of pathophysiology
mandates a systematic approach to identify the molecular
events that cause and perpetuate these chronic, relapsing
inﬂammatory disorders.
In the search for genes that cause IBD, several genetic
linkage studies, which identify the approximate chromosomal
locations of disease susceptibility genes, have been carried
out [3]. This technique, in combination with the more
classical candidate gene approach, led to the identiﬁcation
of the ﬁrst disease-associated variants in the NOD2/CARD15
gene on chromosome 16 [4–6]. More recently, we have
identiﬁed discs, large homolog 5 (DLG5; Drosophila) on chromo-
some 10q23, which encodes a scaffolding protein potentially
involved in the maintenance of epithelial integrity, as an IBD
susceptibility gene [7]. Concomitantly, functional variants in
the solute carrier family 22 (organic cation transporter) genes,
SLC22A4 and 5 on chromosome 5q31, were found to be
associated with CD [8]. The high number of linkage regions in
IBD and the multiplicity of association ﬁndings suggest
enormous complexity behind the polygenic risk between
patients. Genetic susceptibility factors are therefore unlikely
to serve as molecular targets for direct therapeutic applica-
tion. Key molecules in pathophysiology, downstream of
points of convergence between the chains of regulatory
events originating from different etiologic factors, are more
likely targets for successful therapeutic interventions. This
can be illustrated with the example of tumour necrosis factor-
alpha (TNF-a), a molecule that does not appear to be causative
in CD, but allows effective interruption of the inﬂammatory
cascades through administration of a neutralizing, recombi-
nant antibody construct [9]. The example of TNF-a also
illustrates that a successful therapeutic approach may not
target disease-speciﬁc pathophysiology, but rather molecules
that are of general importance for inﬂammation pathophysi-
ology, and therefore involved in a host of inﬂammatory
disorders.
The sequencing of the human genome and the concurrent
establishment of the expressed sequence tag (EST) clone
database [10] have greatly improved the possibility of ﬁnding
new pathophysiology-relevant genes. One technique now
adopted in this latter endeavour is microarray technology,
where the transcripts of thousands of genes can be simulta-
neously investigated. Three exploratory microarray studies
carried out on intestinal mucosa samples to date broadly
concur on the known genes found to be associated with IBD
[11–13].
In the present study, we have used mucosal biopsies
obtained by endoscopy, and not isolated cell populations,
because IBD represents the rare case of a nonmalignant
human disorder in which relevant disease tissue can be
obtained without surgery and without any technical variance
introduced by a cell isolation process. We set up a system for
expression proﬁling using PCR-ampliﬁed cDNA clone inserts
from a large whole genome collection derived from clustered
EST libraries spotted on nylon ﬁlters. This genome-wide gene
set was optimized for clones representing clusters from
unknown ESTs and genes. Due to the clustering algorithm
used, some well-known genes are therefore not represented.
Preliminary experiments have demonstrated a limited over-
lap with the genome-wide arrays from Affymetrix with
reproducible but different ﬁndings generated on both
systems [14]. The two-stage design of the present experiment
used a sensitive radioactive detection method for the array
signals (resulting in a lower dynamic range than Affymetrix
arrays) followed by real-time PCR (TaqMan) for a quantitative
assessment of the changes detected. In carrying out this study,
we aimed to broaden our understanding of gene regulation
events in CD and UC, and identify novel genes involved in
perpetuating inﬂammatory disease progression.
Methods
Patients
Patient group 1. This group was composed of all samples
(representing 31 individuals, recruited between 1999 and
2003) analysed by cDNA microarrays (Table 1). Eleven
individuals (ﬁve females [F]; mean age 51.4 y; range 25–84 y)
were included in the study as the normal population, with
endoscopic and histological examination yielding no signiﬁ-
cant pathological ﬁndings. Indications for colonoscopy in this
group included colonic cancer surveillance and previous
nonspeciﬁc changes in stool habits. To investigate gene
expression in IBD, ten patients with active CD (4F; mean age
33.6 y; range 19–66 y) and ten patients with active UC (2F;
mean age 34.8 y; range 27–51 y) were sequentially recruited.
All endoscopic biopsies were taken from a deﬁned area of the
sigmoid colon (at 20–30 cm measured during withdrawal),
and immediately snap-frozen in liquid nitrogen. A second set
of biopsies was taken from the same region for histological
scoring. Clinical disease activity was documented using
established clinical parameters of the Crohn disease activity
index (CDAI) in CD [15] and the colitis activity index (CAI)
[16,17] for UC patients. Inclusion criteria were clinically
(CDAI . 150 or CAI   4) and endoscopically active disease in
the sigmoid colon at the time of sampling. Patients also had
to be free of all medication used for the treatment of IBD
(other than low-dose 5-aminosalicylic acid [5-ASA]) for a
minimum of 6 wk prior to endoscopy. More than 300 patients
were screened to recruit the study population.
Patient group 2. To verify and investigate the molecular
epidemiology of selected signals seen in genome-wide array
experiments, patient group 1 was extended from 31 to 100
individuals and analysed by quantitative real-time PCR (Table
2). IBD patients used in group 2 consisted of 27 CD patients
(17F; mean age 32.1 y; range 17–45 y) and 35 UC patients (20F;
mean age 33.8 y; range 18–74 y). The patients were recruited
between 1999 and 2004 and were selected using similar
criteria as outlined above, i.e., all patients had active
inﬂammation in the colon and were clinically active (CDAI
. 150 or CAI   4). Patients were allowed 5-ASA or
glucocorticoids, but not immunosuppressants or biologicals.
The normal control population consisted of 21 individuals
(11F; mean age 48.9 y; range 16–84 y), who had no signiﬁcant
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changes in stool habits, abdominal pain, or upper gastro-
intestinal bleeding or cancer surveillance. As disease speciﬁc-
ity controls, 17 patients (9F; mean age 56 y; range 17–80 y)
with colonic disease but not IBD, were also included (Table 2).
These disease speciﬁcity controls (DCs) included nine non-
inﬂamed and eight inﬂamed biopsies samples from patients
with infectious diarrhoea, other forms of gastrointestinal
inﬂammation, or irritable bowel syndrome. No restriction on
medications was speciﬁed in the inclusion criteria for DCs
and all concomitant medications are listed in Table 2. A
minimum of 19 normal controls, 16 UC, 19 CD, and 14 DC
samples were used for each real-time PCR assay, depending
on the availability of the patient samples and the plate layout
at the time the real-time cDNA plates were produced.
Biopsies from all patients in the microarray study were
taken from the sigmoid colon. For the real-time PCR work,
biopsies were also taken from other regions of the large
intestine (Table 2). We conducted extensive preparatory
studies in which we systematically compared the inﬂuence of
anatomical region on the expression proﬁles obtained.
Signiﬁcant differences in expression patterns between the
sigmoid colon, descending colon, and transverse colon/
caecum were not observed (unpublished data). Additionally,
animal data has shown that different regions of the GI tract
(stomach, small intestine, and colon), but not regions within
the colon, were distinguishable by expression proﬁles [18].
We therefore considered regions within the large bowel to be
equivalent and that sampling from different areas of the large
bowel would have negligible effect on differential gene
expression.
Informed Consent and Approval by the Ethics Committee
All patients included in this study consented to additional
research biopsies being taken 24 h prior to endoscopy. One
patient withdrew the genotype part of his consent. The
procedures in the study protocol were approved by the Ethic
Committee of the Medical Faculty of the Christian-Albrechts-
University prior to the start of the study.
Target Preparation and Hybridisation to cDNA Microarrays
cDNA clone inserts from 88 microtiter plates containing
384 wells (i.e., 33,792 inserts total) from the Human UniGene
set RZPD 1 clone set (German Resource Center for Genome
Research [RZPD], Berlin, Germany; http://www.rzpd.de/) were
ampliﬁed by PCR and spotted onto nylon ﬁlters [14]. Since
the redundancy of this clone set was previously estimated to
be approximately 1.44-fold [19], the 33,792 clones on the
cDNA microarray represent approximately 23,000 unique
transcripts. Total RNA was isolated from snap-frozen
biopsies, and mRNA isolation, radioactive labelling of mRNA,
and subsequent steps (hybridisation of the radiolabelled
target, washing, and scanning of ﬁlters) were carried out as
previously described [14].
Data Analysis
Image gridding and spot quantitation were carried out
using VisualGrid software (GPC Biotech, Martinsried, Ger-
many; http://www.gpc-biotech.com), and results were im-
ported into a custom-made database for further analysis.
The ranked expression data distribution was found to follow
Zipf’s law, and the log-transformed datasets were normalized
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Expression Profiling in IBDfollowing this principle [20,21]. Any hybridisation signals that
had a value that fell below two standard deviations of the
mean background were considered as indistinguishable from
background and were set to zero. In the few cases where
duplicate expression values for the same genes were not
similar (outliers or false positives), all readings for this gene
were eliminated. The entire microarray dataset was not
normally distributed and, therefore, in order not to assume a
speciﬁc distribution of data, signiﬁcantly differentially
regulated genes between conditions were identiﬁed by a
nonparametric test (Mann-Whitney U test). Fold-changes
were calculated based on the median of each experimental
group.
In order to identify potential gene function, the SOURCE
database (http://source.stanford.edu) was used to retrieve
Gene Ontology terms, after genes expressed more than once
were removed (Dataset S1). Systematic analysis of functional
groups in microarray datasets is a complex issue, which is still
under discussion. We used the published method of Tavazoie
et al. [22] to support the validity of the three functional
groups we selected for discussion. Brieﬂy, this method
determines whether the selection of a subset of genes results
in over-representation/enrichment of functional groups,
compared to the genes in these functional groups on the
entire array. We compared our gene ﬁndings with those from
three other smaller IBD studies [11–13] to determine if the
proposed disease mechanisms were similar.
Quality Controls and Assessment of Technical Variance
In order to ascertain data reliability and reproducibility,
the expression levels of each of the 33,792 clones were
measured in duplicate in each experiment. The resulting
correlation coefﬁcient was very high (r¼0.99), indicating that
hybridisation signals were highly reproducible (unpublished
data). To assess microarray and hybridisation-based exper-
imental variability, hybridisation was performed on ﬁve
separate microarrays using the same RNA sample (extracted
from an intestinal surgical specimen; unpublished data). We
performed pairwise comparisons between all possible combi-
nations of ﬁlters. We computed the fold-change observed for
each of the 33,792 replicate signals, which should theoret-
ically be 1 (i.e., no fold-change) in all cases, but varies due to
experimental noise. We recorded the fold-change observed at
the 95th percentile of the distribution for each pairwise
comparison and took the average of these values. This
provided us with a fold-change of 1.2 as the signiﬁcance
threshold to claim differential expression. This threshold of
positive gene identiﬁcation is lower than reported for many
studies; i.e., array studies using Affymetrix arrays usually
consider a 2-fold or greater change between two conditions
as signiﬁcant. It is worth noting that common ﬂuorescently
labelled oligonucleotide-based array systems (i.e., Affymetrix)
amplify the signal with biotin-streptavidin complexes, which
is not the case with radioactive detection, hence the fold-
change cutoff criteria are not comparable between these two
platforms. However, we substantiated our threshold ﬁndings
Table 2. Characteristics of Patient Group 2, Including DCs
Characteristic Hospitalized Normal Patients CD Patients UC Patients DC Patients
Number of patients 21 27 35 17
Sex (F/M) (11F/10M) (17F/10M) (20F/15M) (9F/8M)
Age (y), mean (range) 48.9 (16–84) 32.1 (17–45) 33.8 (18–74) 56 (17–80)
Region of biopsy
Sigmoid colon 13 26 35 16
Descending colon 1 1 0 0
Caecum 7 0 0 0
Transverse colon 0 0 0 1
Inflammation activity
a
Active 0 27 35 8
Inactive 21 0 0 9
Activity index, mean (range)
b NA 300 (250–450) 8 (6–9) NA
Diagnosis (DC patients)
Infectious diarrhoea NA NA NA 8
Gastrointestinal inflammation NA NA NA 7
Irritable bowel syndrome NA NA NA 2
Disease location (IBD patients only)
Ileocaecal NA 10 0 NA
Pancolitis NA 11 17 NA
Distal colon NA 6 18 NA
Fistulae NA 5 0 NA
Stenoses NA 4 0 NA
Medication
No treatment 14 9 11 9
Steroids 0 11 11 1
5-ASA 0 9 18 1
NSAID 2 0 1 3
Antibiotic 1 2 0 4
Other 4 2 4 4
aInflammation activity of biopsied site, as observed by the endoscopist.
bCDAI and CAI reported only for CD and UC patients, respectively.
5-ASA, 5-aminosalicylic acid; DC, disease specificity control patients; NA, not applicable; NSAID, nonsteroidal anti-inflammatory drug.
DOI: 10.1371/journal.pmed.0020199.t002
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Expression Profiling in IBDby carrying out additional statistical analysis with an addi-
tional well-established microarray analysis package. Using
signiﬁcance analysis of microarrays (SAM) software (set to a
maximum false discovery rate of 4%) to retest our analysis
based on fold-changes, 10% of our signiﬁcantly regulated
genes were rejected by SAM. This difference comes mainly
from genes that have barely passed the signiﬁcance level of
our own analysis (unpublished data). Heat maps of differ-
entially regulated genes were generated using Spotﬁre
Decision site 8.1 software (Spotﬁre, Somerville, Massachu-
setts, United States; http://www.spotﬁre.com/).
Verification of Clone Sequences
Differentially expressed clones were bidirectionally se-
quenced from PCR products of clone inserts or bacterial
plasmids as previously described [14]. Contigs were generated
if the clone ends overlapped (Sequencher software; Gene
Codes Corporation, Ann Arbor, Michigan, United States) and
identiﬁed by BLAST searching (http://www.ncbi.nlm.nih.gov/
BLAST/). All genes reported in this study have been sequence-
veriﬁed in this manner. Incorrect clone annotations were
found in 27% of cases. This annotation error rate is similar to
that reported for IMAGE clone sets in other studies [23,24].
Independent Quantitation of Microarray Results by
TaqMan PCR
Selected gene expression signals were independently
quantitated with real-time PCR (TaqMan) on patient group
2. Probes and primers were either designed to non-redundant
sequences using Primer Express V2.0 (Applied Biosystems,
Foster City, California. United States), or ordered from
Applied Biosystems as Assays-on-Demand Gene Expression
Assays (Table S1). Total RNA (1 lg) was reverse-transcribed to
cDNA according to the manufacturer’s instructions (Multi-
Scribe Reverse Transcriptase, Applied Biosystems). Reactions
were carried out on the ABI PRISM Sequence 7700 Detection
System (Applied Biosystems) and relative transcript levels
were determined using b-actin as the endogenous control
gene. Statistically signiﬁcant differences between control and
IBD samples were determined using a Mann-Whitney U test.
A p-value of less than 0.05 was considered signiﬁcant.
Histological Rating of Disease Activity
A single pathologist (Y. G.), blinded to disease status and
the experimental results, performed the histological rating of
inﬂammatory activity in biopsy samples taken from the same
anatomical location as the samples used for microarray
experiments. The normal group showed no pathologic signs
of activity in the histological examination (unpublished data).
As detailed in Table 1, acute inﬂammatory activity and
chronic changes were rated, with additional endoscopic
ﬁndings also noted.
Immunohistochemistry
In order to determine protein localization, parafﬁn-
embedded biopsies from normal controls (n ¼ 5) and from
patients with CD (n¼5) and UC (n¼6), which were obtained
in parallel from the same sites as the biopsies used for the
expression analysis studies, were analysed. This procedure is
described in more detail elsewhere [25]. Brieﬂy, 7-lm sections
were subjected to heat-induced antigen retrieval in 0.01 M
EDTA solution (pH 8) for 10 min. After blocking in a solution
of 0.75% BSA in PBS for 20 min, the sections were washed
three times in PBS and incubated for 1 h with the respective
primary antibodies (monoclonal carcinoembryonic antigen-
related cell adhesion molecule 1 [CEACAM1] 4D1/C2, protein
kinase C beta 1 [PRKCB1; Pharmingen, San Diego, California,
United States], and casein kinase 1, delta [[CSNK1D; Santa
Cruz Biotechnology, Santa Cruz, California, United States].
After washing in PBS (three times for 10 min), the sections
were incubated with peroxidase-conjugated rabbit anti-
mouse secondary antibody (Sigma, Deisenhofen, Germany;
1:100) for 30 min, washed, and stained with goat anti-rabbit
IgG (Sigma; 1:200, 30 min), before processing with diamino-
benzidine and embedding in Aquatek (Merck, Hawthorne,
New York, United States). For speciﬁcity controls, (i) the
primary antibodies were omitted and (ii) normal sera were
used from the species in which the primary antibodies were
raised. No speciﬁc staining could be detected using either of
these combinations (unpublished data).
Prediction of Function in Unknown Genes
In order to identify novel genes, unknown differentially
regulated clones were examined in more detail. cDNA clone
sequences were searched against the GenBank nonredundant
database by means of BLAST searching. The best BLAST hit
(sequence identity close to 100%) was used to extend the
sequences to longer mRNA transcripts. InterPro (http://
www.ebi.ac.uk/InterProScan), SMART (http://smart.embl-hei-
delberg.de) and Pfam (http://www.sanger.ac.uk/Software/Pfam)
search methods (with standard parameter sets) were used to
detect known protein domains and functional sequence
motifs in putative open reading frames (ORFs) longer than
100 amino acids. Close homologies of the ORFs were found
through their association to UniGene clusters in humans and
other species. In cases of ORFs without a detectable
homology to known genes, these transcripts were mapped
to genomic locations by BLAST searching and examined in
terms of their genomic context. Additionally, we used a
previously published method for prediction of function of
mouse transcripts [26], and applied a similarity analysis in
order to predict the function based on common regulation
patterns between known functional groups and unknown
transcripts.
Results
Expression Profiles of the IBD Colonic Mucosa
Samples from sigmoid colon that were taken from normal
controls (n¼11), patients with CD (n¼10), and patients with
UC (n ¼ 10) were used to compare differences between
normal and inﬂamed intestinal mucosa. After implementing
Figure 1. Heat Map of Differentially Expressed Genes in Normal Controls Compared to IBD
(A) The top 40 up-regulated and the top 40 down-regulated between normal controls (n ¼ 11) and CD patients (n ¼ 10).
(B) The top 40 up-regulated and the top 40 down-regulated genes between normal controls (n ¼ 11) and UC patients (n ¼ 10).
Selection criteria were p   0.0015 (based on Mann-Whitney U test) and a fold-change of 1.2 or greater. All genes presented in this heat map were
sequence verified.
DOI: 10.1371/journal.pmed.0020199.g001
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Expression Profiling in IBDTable 3. Functional Groups of Differentially Regulated Genes
Functional Category Symbol Name NC Versus CD NC Versus UC
Fold-Change p-Value Fold-Change p-Value
Immune and Inflammatory
Response
— Transcribed sequence with strong similarity to protein pir:I38067
(H. sapiens) I38067 nitric-oxide synthase
.10 0.001066 .10 0.000363
IGHG1 Immunoglobulin heavy constant gamma 1 (G1m marker) .10 0.000783 .10 0.000023
IGH@ Immunoglobulin heavy locus 5.5 0.000380 .10 0.000023
ASS Argininosuccinate synthetase 2.83 0.000170 2.91 0.000068
ITGB2
a Integrin, beta 2 (antigen CD18 (p95), lymphocyte function-associated
antigen 1; macrophage antigen 1 (mac-1) beta subunit
2.64 0.000380 2.29 0.000170
DAF Decay accelerating factor for complement (CD55, Cromer blood group
system)
1.83 0.000380 3.17 0.000040
IER3 Immediate early response 3 1.95 0.000006 2.31 0.001100
HLA-B Major histocompatibility complex, class I, B 1.96 0.000788 2.19 0.000380
TNFRSF6B Tumor necrosis factor receptor superfamily, member 6b, decoy 1.87 0.000023 2.35 0.000380
PLA2G2A
a Phospholipase A2, group IIA (platelets, synovial fluid) 1.72 0.000170 2.37 0.001100
HLA-DRB3 Major histocompatibility complex, class II, DR beta 3 1.71 0.000170 2.09 0.000006
HAMP Hepcidin antimicrobial peptide  1.51 0.000788  1.5 0.001100
C5 Complement component 5  1.42 0.000108  1.28 0.000788
BIRC4 Baculoviral IAP repeat-containing 4  1.41 0.000006  1.36 0.000255
HLA-A Major histocompatibility complex, class I, A 2.17 0.000170
IL1R1 Interleukin 1 receptor, type I 1.32 0.000380
LTB4R2 Leukotriene B4 receptor 2  1.59 0.000068
ALOX5 Arachidonate 5-lipoxygenase  1.58 0.000788
CYLD Cylindromatosis (turban tumor syndrome)  1.53 0.001111
ALOX5AP Arachidonate 5-lipoxygenase-activating protein  1.52 0.000550
ADORA3 Adenosine A3 receptor  1.48 0.000068
HLA-DQA1 Major histocompatibility complex, class II, DQ alpha 1  1.47 0.000108
CDKN1A Cyclin-dependent kinase inhibitor 1A (p21, Cip1)  1.46 0.000788
CCL28 Chemokine (C-C motif) ligand 28  1.45 0.001100
MICA MHC class I polypeptide-related sequence A  1.4 0.001100
RNPEP Arginyl aminopeptidase (aminopeptidase B)  1.37 0.000170
MASP1 Mannan-binding lectin serine protease 1  1.36 0.001100
IGKC
a Immunoglobulin kappa constant 3.42 0.000380
P4HB Proline 4-hydroxylase 2.37 0.000023
NOS2A Nitric oxide synthase 2A (inducible, hepatocytes) 2.03 0.000550
CEACAM1
a Carcinoembryonic antigen-related cell adhesion molecule 1 2.01 0.000788
IGLL1 Immunoglobulin lambda-like polypeptide 1 1.94 0.000380
IFITM1 Interferon induced transmembrane protein 1 (9–27) 1.65 0.000068
CHUK Conserved helix-loop-helix ubiquitous kinase 1.51 0.001100
EGLN3 Egl nine homolog 3 (Caenorhabditis elegans) 1.42 0.000170
MYBL2 V-myb myeloblastosis viral oncogene homologue (avian)-like 2 1.35 0.000108
ALDH2 Aldehyde dehydrogenase 2 family (mitochondrial) 1.28 0.00110
BST1 Bone marrow stromal cell antigen 1  1.34 0.000550
Oncogenesis, Cell Proliferation,
and Growth
TIMP1 Tissue inhibitor of metalloproteinase 1 2.35 0.000068 4.12 0.000006
PLA2G2A
a Phospholipase A2, group IIA (platelets, synovial fluid) 1.72 0.00017 2.37 0.0011
CAPNS1 Calpain, small subunit 1 1.24 0.000255 1.36 0.000068
GAS2 Growth arrest-specific 2  1.54 0.00055  1.45 0.0011
STAG1 Stromal antigen 1  1.46 0.000011  1.31 0.00038
DAB2 Disabled homolog 2, mitogen-responsive phosphoprotein (Drosophila)  1.33 0.00004  1.21 0.0011
DNAJB5 Dnaj (Hsp40) homolog, subfamily B, member 5 1.64 0.00055
CSNK1D Casein kinase 1, delta 1.54 0.0011
NME2 Non-metastatic cells 2, protein (NM23B) expressed in 1.28 0.0011
NEDD9 Neural precursor cell expressed, developmentally down-regulated 9  1.64 0.000108
CYLD Cylindromatosis (turban tumor syndrome)  1.53 0.001111
TSSC1 Tumor suppressing subtransferable candidate 1  1.51 0.000068
CISH Cytokine inducible SH2-containing protein  1.49 0.00055
Rock1 Rho-associated, coiled-coil containing protein kinase 1  1.48 0.00017
PPP2CA Protein phosphatase 2 (formerly 2A), catalytic subunit, alpha isoform  1.48 0.00004
PICALM Phosphatidylinositol binding clathrin assembly protein  1.46 0.00004
WIT-1 Wilms tumor associated protein  1.45 0.00055
FLJ13352 Hypothetical protein FLJ13352  1.4 0.00038
RASA1 RAS p21 protein activator (GTPase-activating protein) 1  1.39 0.0011
CDK5RAP1 CDK5 regulatory subunit associated protein 1  1.37 0.000788
RAD1 RAD1 homolog (Saccharomyces pombe)  1.33 0.00055
CENPE Centromere protein E, 312 kDa .10 0.00017
TFF1
a Trefoil factor 1 (breast cancer) 3.06 0.000006
S100P
a S100 calcium binding protein P 2.61 0.000108
S100A6 S100 calcium binding protein A6 (calcyclin) 1.84 0.000068
PRKCN Protein kinase C, nu 1.68 0.0011
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Expression Profiling in IBDestablished analysis criteria, 650 genes were found to be
differentially regulated between normal controls and at least
one of the IBD subtypes. Of these 650 genes, 500 transcripts
(81 up-regulated) were identiﬁed as differentially regulated
between normal controls and CD patients. Two hundred and
seventy-two differentially regulated transcripts (157 up-
regulated) were identiﬁed between normal controls and UC
patients. At our cutoff level, 122 genes were dysregulated in
both diseases, and approximately 44% and 36% of all
differentially regulated genes represented unknown genes
in CD and UC, respectively. Heat maps shown in Figure 1
represent the top 40 up- and down-regulated genes for each
experimental group. The complete list of all differentially
regulated genes identiﬁed in this study (including reference
to chromosomal areas previously implicated in IBD linkage
studies) can be found in Table S2.
In order to delineate the molecular ﬁngerprint of each of
the two disease subtypes, the differentially regulated genes
were assigned to functional groups based on classiﬁcation by
Gene Ontology (http://www.geneontology.org/) and references
in the literature. The majority of genes fell into the following
groups, which are listed as such in Table 3: immune and
inﬂammatory responses; oncogenesis, cell proliferation, and
growth; and structure and permeability. The signiﬁcance of
this observation was tested according to Tavazoie et al. [22].
The p-value for the overall signiﬁcance for an over-
representation of genes in the category ‘‘immune and
inﬂammatory responses’’ was 0.00062. This enrichment was
mainly driven by genes that were up-regulated in CD (p ¼
0.0011) and UC (p ¼ 0.0026). An enrichment of genes
associated with cell growth and proliferation (p ¼ 0.0404)
was driven by genes that were up-regulated in UC, while
genes associated with structure and permeability (p ¼ 0.0309)
are mostly found in the category of genes up-regulated in CD.
Functional Prediction of Unknown Genes
To decipher potential roles for unknown genes, we further
analysed some of the top differentially expressed unknown
genes between normal controls and IBD (Table 4). Some of
the transcripts had no known sequence homologies (e.g.,
GenBank accession number BC006384), whereas others were
in UniGene clusters with sequences homologous to structural/
cytoskeletal proteins (e.g., AK022544). Additionally, some
transcripts showed sequence homology to cell adhesion genes
(e.g., N48794 and AF087994). The gene represented by
GenBank accession number AL117511 may be involved in
vacuolar sorting, and AK056932 is a putative transmembrane
phosphate acyltransferase. Additional gene products contain
DNA-binding domains and may function as transcription
factors (e.g., N39296 and AW953679), or represent a possible
kinase (e.g., AB067499) or may play a role in intracellular
signalling (e.g., BC008744). Of the unknown genes analysed,
90% have homologues in other species, lending credibility to
the hypothesis that these as yet uncharacterised genes must
have an important function since they are conserved in the
evolutionary process. Additionally, predictions based on
Table 3. Continued
Functional Category Symbol Name NC Versus CD NC Versus UC
Fold-Change p-Value Fold-Change p-Value
S100A11
a S100 calcium binding protein A11 (calgizzarin) 1.56 0.000011
CAPN1 Calpain 1 (mu/I) large subunit 1.37 0.000108
MYBL2 V-myb myeloblastosis viral oncogene homolog (avian)-like 2 1.35 0.000108
NDRG3 NDRG family member 3  1.24 0.0011
Structure and Permeability TIMP1 Tissue inhibitor of metalloproteinase 1 2.35 0.000068 4.12 0.000006
COL6A2 Collagen, type VI, alpha 2 2.50 0.000011 2.11 0.000023
MMP2 Matrix metalloproteinase 2 1.98 0.000255 1.80 0.000108
MUC1
a Mucin 1, transmembrane 1.68 0.00055 1.74 0.000011
MUC13 Mucin 13, epithelial transmembrane 1.35 0.00017 1.64 0.000023
CDH11 Cadherin 11, type 2, OB-cadherin (osteoblast) 1.59 0.00004 1.48 0.00017
DKFZp547A023 Hypothetical protein dkfzp547a023  1.65 0.000011  1.47 0.00055
FLJ36812 Hypothetical protein FLJ36812  1.42 0.000023  1.31 0.000023
CLDN4 Claudin 4 1.70 0.00017
CLDN3 Claudin 3 1.47 0.000788
SPARC
a Secreted protein, acidic, cysteine-rich (osteonectin) 1.47 0.0011
COL8A2 Collagen, type VIII, alpha 2  1.62 0.00038
COL15A1 Collagen, type XV, alpha 1  1.55 0.00055
PRKCB1
a Protein kinase C, beta 1  1.5 0.000788
ROCK1 Rho-associated kinase beta  1.48 0.00017
LIM LIM protein (similar to rat protein kinase C-binding enigma)  1.48 0.000788
- Transcribed sequences (GenBank N48794)  1.46 0.000006
RDX Radixin  1.42 0.00055
ANK3 Ankyrin 3, node of Ranvier (ankyrin G)  1.35 0.00038
OCLN Occludin  1.34 0.000788
FLJ25778 Hypothetical protein FLJ25778  1.33 0.0011
CLTC Clathrin, heavy polypeptide (Hc) 2.91 0.00038
P4HB Procollagen-proline, 2-oxoglutarate 4-dioxygenase 2.35 0.000023
COL21A1 Collagen, type XXI, alpha 1 1.61 0.000788
Minus signs in the columns ‘‘Fold-Change’’ indicate down-regulation between normal controls (NC) and IBD individuals.
aGene previously reported to be differentially expressed in IBD [11–13]. All data based on microarray results.
DOI: 10.1371/journal.pmed.0020199.t003
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Expression Profiling in IBDsimilarities of regulation patterns of known functional groups
are listed in Table 4.
Independent Quantification by Fluorescent Real-Time PCR
Real-time TaqMan PCR on selected transcripts was carried
out as a sensitive independent veriﬁcation method of the
microarray results (Figure 2). The population of 31 patients
used for microarray studies (group 1) was extended for the
real-time PCR experiments to 100 patients (group 2). Group 1
patients did not exhibit signiﬁcant differences from group 2
patients on the level of gene expression, as veriﬁed by
groupwise comparison. Genes for real-time PCR were chosen
based upon their dysregulation in IBD, and representation
within the three main functional groups discussed later.
Differentially regulated transcripts of unknown function were
also included. As an additional control for the suitability of
the samples and the stability of the overall approach, TNF-a
and interleukin-8 (IL-8) were used, as small soluble cytokine
mediators not present on the array system but known as
hallmarks of IBD pathophysiology. As expected, overexpres-
sion of IL-8 in both CD and UC and TNF-a in CD was observed
in the samples used. An additional 15 genes on the micro-
arrays were then analysed in the extended real-time patient
cohort (i.e., patient group 2). The 15 real-time PCR experi-
ments that were carried out are summarised in Figures S1 and
2 and Table 5. Genes that were signiﬁcantly up-regulated in
both microarray and real-time PCR in the two IBD subtypes
(compared to normal controls), include cadherin-11 (CDH11),
decay accelerating factor for complement (DAF), immunoglobulin heavy
constant gamma 1 (IGHG1), mucin 1 (MUC1), phospholipase A2,
group IIA (PLA2G2A), and tissue inhibitor of metalloproteinase 1
(TIMP1).T h eu n k n o w ng e n e ,DKFZp547A023 (GenBank
accession number AK022544; see Table 4), was conﬁrmed by
real-time PCR to be down-regulated in both disease groups. In
the case of cylindromatosis (CYLD), calcitonin gene-related peptide-
receptor component protein (RCP9), LIM protein (LIM), occludin
(OCLN), Rho-associated, coiled-coil containing protein kinase 1
(ROCK1), and zinc ﬁnger, CCHC domain containing 4 (ZCCHC4),
the microarray results showed that these genes were down-
regulated in both IBD subtypes, but failed to reach signiﬁ-
cance in the UC cohort. However, results from the extended
real-time analysis showed that these six genes were signiﬁ-
cantly down-regulated in both IBD subtypes. PH domain-
containing protein (PP9099, BC008744; see Table 4) was up-
regulated in both diseases on the microarray, but our
microarray cutoff criteria were not reached in the CD
population. Real-time analysis on the extended IBD popula-
tion demonstrated this gene was signiﬁcantly up-regulated in
both IBD subtypes. One gene, trefoil factor 1 (TFF1), was found
to be up-regulated in UC on the microarray but failed to reach
signiﬁcance for CD, a result that was conﬁrmed by real-time
PCR in the extended group 2 samples. These results strongly
emphasize the importance of using a high-throughput
quantitative technique to follow positive signals from micro-
array experiments into larger and diverse patient populations.
Expression Profiles in Non-IBD Disease Samples
Disease speciﬁcity is an important issue in the detection of
differential gene expression between IBD and normal
controls. Real-time PCR was carried out on patients that
had colonic disease (DC, n ¼17), but not IBD (Figures S1 and
3). These DC samples were again divided into noninﬂamed
and inﬂamed conditions. No signiﬁcant difference was
observed between the expression of any of the 15 genes
tested between normal controls and noninﬂamed disease
speciﬁcity controls. Eight genes (CYLD, DAF, DKFZp547A023,
MUC1, OCLN, PLA2G2A, TIMP1, and ZCCHC4; Table 5) were
signiﬁcantly differentially regulated between normal controls
and inﬂamed DC, and the direction of change was the same as
that observed in IBD. This observation suggests that these
eight gene ﬁndings probably reﬂect general inﬂammation
pathophysiology rather than events speciﬁc for IBD. How-
ever, unlike in the IBD cohort, the expression of the
remaining seven genes (CDH11, IGHG1, PP9099, TFF1, LIM,
ROCK, and RCP9; Table 5) was not signiﬁcantly different in
between normal controls and the inﬂamed DC group.
Localisation by Immunohistochemistry
As expression analysis in complex tissues does not allow an
identiﬁcation of the cells responsible for the signal, we used
immunohistochemistry to exemplify the approach to genes of
interest. Parafﬁn-embedded sections of samples from the
group 1 patients were used. Genes were chosen on the basis
that they were formerly not associated with IBD etiopatho-
genesis and represented a gene in our three main functional
groups. Consistent with increased transcript levels measured
by microarrays, a marked up-regulation of CEACAM1
protein was seen in IBD when compared to normal controls
(Figure 4A). Immunoreactivity was found in the apical
epithelial lining in the normal mucosa, whereas it extended
down into the epithelial cells of the crypts in the inﬂamed
tissue of CD and UC patients. A staining of vascular
structures and mononuclear cells, most likely with a
lymphocytic phenotype, was only detected in the lamina
propria of inﬂamed biopsies.
CSNK1D immunohistochemistry staining (Figure 4B) dem-
onstrated expression in the colon, but the modest up-
regulation seen in CD in the microarray was not detected
by immunohistochemistry. In the biopsies from CD patients,
staining of the apex of the crypts could be observed.
Immunoreactivity revealed a strong granular staining pattern
of intestinal epithelial cells in the normal and UC group,
which was located basolaterally.
Staining of PRKCB1 (Figure 4C), that appeared to be down-
regulated in the microarray results showed only a weak
staining in the apical epithelial layer in the normal and CD
mucosa, whereas a stronger staining was present in the UC
group. Furthermore, scattered lamina propria mononuclear
cells underlying the epithelial layer were also positive.
Interestingly, in the CD group, immunoreactivity was found
nearlyexclusivelyinthemarginal zoneofsmalllymphfollicles.
Discussion
The current understanding of IBD pathogenesis is that of a
complex interplay of both genetic and environmental factors
that results in an aberrant immune response of the intestinal
mucosa. In the past few years, signiﬁcant progress has been
made in elucidating the root causes of CD and UC, with at
least three genes now identiﬁed in which sequence variations
confer disease susceptibility [4–8]. The advent of genomic
technologies such as genome-wide microarrays can be used to
dissect genes relevant to disease pathophysiology, and allows
an unbiased view of both speciﬁc and nonspeciﬁc (such as
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Expression Profiling in IBDresponse to inﬂammation) events. In this study we aimed to
use the power of genome-wide expression analysis by micro-
array to dissect novel important regulatory molecules down-
stream of the multiple primary genetic causes that may
initiate the pathophysiologic cascade of inﬂammation in IBD.
Therefore, both speciﬁc and nonspeciﬁc dysregulation may
yield valuable information in identifying new targets for
future disease therapy.
In the present study, a total of 650 genes were differentially
regulated between normal controls and the two IBD subtypes.
More speciﬁcally, 500 and 272 differentially regulated tran-
scripts were identiﬁed between normal controls and CD and
UC patients, respectively. Of note, we observed an imbalance
between over- and underexpressed genes in the IBD subtypes.
In CD, approximately 84% of differentially expressed genes
were found to be down-regulated, compared with 42% of
genes in UC. Although this is an interesting ﬁnding, it is not
prudent at this stage to suggest that broad up- (in UC) or
down-regulation (in CD) of genes is a distinctive disease
feature, as this ﬁnding is highly inﬂuenced by types and
numbers of genes that are present on any given microarray
system. Without exception, none of the 122 differentially
expressed genes that were found in both CD and UC, was
found to be over expressed in one disease and under
expressed in the other. This ﬁnding strongly supports the
robustness of the observation and the notion of a shared
general inﬂammation proﬁle underlying two clinically diver-
gent forms of IBD, whereas more speciﬁc events in the
pathophysiologic cascade could be disease-speciﬁc.
Disease divergence is also supported by a previous IBD
microarray study. Interestingly, when we compared our
ﬁndings with other CD and UC microarray studies [11–13],
we observed few overlaps at the level of individual gene
expression (see Table 3), but we did ﬁnd a high degree of
concordance at the level of proposed functional groups and
potential mechanisms relevant to IBD (see discussion below).
This study therefore not only complements these previous
studies, but adds to our knowledge of disease, particularly as
the Human UniGene RZPD Set 1 is enriched for as yet
unannotated ESTs and, therefore, varies signiﬁcantly from
the commercially available arrays previously used [11,12]. As
far as we are aware, the present study is the ﬁrst to report a
systematic assessment of novel unknown genes that might
play a role in IBD pathophysiology (44% and 36% of
differentially regulated genes identiﬁed in CD and UC
respectively are, as of yet, not annotated).
The differentiation between CD and UC is a long-debated
clinical problem. The large overlap that is seen in patho-
physiology is also seen in clinical course. With the exception
of gradual differences in activity, all established medical
therapies used for colonic inﬂammation in IBD are appli-
cable to both CD and UC [27]. A considerable percentage of
patients appear to change clinical presentation during the
course of the disease and are re-diagnosed with one of the
other two subforms of IBD. Because of this scenario, the
design of the present study did not intend to provide any
diagnostic test to differentiate between CD and UC. As a
matter of fact, at least one disease gene identiﬁed for IBD
shows association with both CD and UC [7]. Therefore, the
Figure 2. Microarray Results and Corresponding Quantitative Real-Time
PCR for Differentially Regulated Genes in CD or UC Compared to Normal
Controls
Genes were chosen on the basis of their dysregulation in IBD and
represent both known genes from functional groups discussed and
genes of unknown function. Quantitative real-time PCR was carried out
on individual samples from group 2 patients (14–18 normal controls, 19–
33 UC, and 17–22 CD samples, depending on the availability of the
patient samples at the time the plates were produced), except for IL-8
and TNF-a (not on array), which were tested in group 1 patients (11
normal controls, ten UC, and ten CD patient samples) as a proof-of-
principle measure. The extended cohort of group 2 patients includes
those with active disease and using anti-inflammatory drugs (but not
immunosuppressants or biologicals), whereas group 1 patients had
active disease and were medication-free for 6 wk. Results are
summarised by a ratio of medians (CD:normal or UC:normal). Complete
results, including box-plots and number of samples analysed in each
assay, are included in Figure S1. All results were significantly differentially
regulated except for marked results; single dagger indicates that array
result was not significant (p . 0.0015 or fold-change , 1.2); asterisk
indicates that real-time PCR result was not significant (p . 0.05). A
dashed line represents the fold-change level of 1.2.
DOI: 10.1371/journal.pmed.0020199.g002
Figure 3. Quantitative Real-Time PCR Results between Normal Controls
and Both Non-Inflamed and Inflamed Disease Specificity Controls
Quantitative real-time PCR was carried out on individual samples from
group 2 patients (including seven or eight inflamed and seven to nine
non-inflamed DCs, depending on the availability of cDNA at the time the
plateswereproduced).TheDCsincludepatientswithinfectiousdiarrhoea,
gastrointestinalinflammation,orirritablebowelsyndrome.Patientsinthis
group were not on immunosuppressants or biologicals, but the use of
anti-inflammatorydrugswasallowed.Resultsaresummarisedbyaratioof
medians (inflamed DC:normal or non-inflamed DC:normal). Results
marked with an asterisk indicate that the real-time PCR result was
significant (p , 0.05). Complete results, including box-plots and sample
numbers analysed in each assay, are included in Figure S1.
DOI: 10.1371/journal.pmed.0020199.g003
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Expression Profiling in IBDoverlap in etiologic factors and pathophysiology between
both subforms of IBD could be larger than expected.
Interpretingthefunctionalconsequencesofchangesingene
expressionobservedinmicroarrayexpressionscreeningisone
ofthemajorgoalsofexploratorymicroarraydataanalysis.One
method used to attempt functional interpretation of micro-
array data is the use of annotation-based pathway databases
such as Gene Ontology (GO). The use of GO does have its
limitations,inparticulartheamountandqualityofannotation
[28], but it does allow a broad overview of terms to decipher
gene pathways. In the present study, we supplemented GO
terms, with literature references, and could classify differ-
entially expressed genes into three major groups: immune and
inﬂammatory response; oncogenesis, cell proliferation, and
growth; and structure and permeability (see Table 3).
Immune and Inflammatory Response
Compared to normal mucosa, many genes associated with
an aberrant immune response were identiﬁed (enrichment
signiﬁcance for this functional group: p ¼ 0.00062; category
‘‘Immune and Inﬂammatory Response,’’ Table 3). Probably
more than any other organ in the body, the intestine is a
hostile environment, and it is not surprising that a general
up-regulation of immune response (enrichment signiﬁcance p
¼ 0.000973) and antigen presentation (enrichment signiﬁ-
cance p ¼ 0.00298) are a common feature of both IBD
subtypes, considering the mucosal injury associated with
these diseases. In contrast to these shared proﬁles, leuko-
triene biosynthesis appears to be more strongly associated
with CD (enrichment signiﬁcance p ¼ 0.00483). With the
exception of phospholipase A2, group IIA (PLA2G2A), which has
an inferred role in prostaglandin and leukotriene metabolism
and was up-regulated in both subtypes, genes associated with
leukotriene metabolism, such as arachidonate 5-lipoxygenase
(ALOX5), arachidonate 5-lipoxygenase-activating protein (ALOX5-
AP), leukotriene B4 receptor 2 (LTB4R2), and arginyl amino-
peptidase (aminopeptidase B; RNPEP) were signiﬁcantly down-
regulated in the CD proﬁle (Table 3). In the same vein, the
marked down-regulation of CYLD is of interest as this gene
has been identiﬁed as a key negative regulator of nuclear
factor-kappa B (NF-jB) regulation [29–31]. Recent in vitro
studies on CYLD regulation have uncovered a novel
autoregulatory pathway in which up-regulation of CYLD,
due to activation of NF-jB by TNF-a and bacteria, leads in
turn to down-regulation of NF-jB signalling [32]. Although
real-time analysis showed that this gene was also down-
regulated in UC, decreased CYLD expression may represent
an inﬂammation control response that is lost or impaired in
some way in IBD. Similarly, inhibition of NF-jB signalling can
be mediated by nitrogen oxide (NO) through the up-regulation
of nitrogen oxide synthases (encoded by NOS2A, Table 3),
which produces NO from arginine, along with other genes
associated with proline and arginine metabolism, such as
proline 4-hydroxylase (P4HB, Table 3) and aldehyde dehy-
drogenase 2 (ALDH2, Table 3), suggests over stimulation of
this metabolic pathways in the UC proﬁle. It is worth noting
that it is not clear whether NO is deleterious or beneﬁcial in
gastrointestinal disease [33]. However, considering the well-
documented potent inﬂammatory role NF-jB activation has
in IBD [29–31], further examination of this complex issue is
well worthwhile.
Finally, within this gene category, expression of CEACAM1
(a known neutrophil activation marker and regulator of T cell
function [34,35]) was examined by immunohistochemistry.
We have shown that this protein is present in blood or
lymphatic vessels of the inﬂamed mucosa (Figure 4A, insets),
consistent with its role in angiogenesis [36]. Inﬁltrating
immune cells in the lamina propria were stained by anti-
CEACAM1 antibody in CD, but not in UC, suggesting that
Figure 4. Immunohistochemical Localization of CEACAM1, CSNK1D, and
PRKCB1 in Colonic Mucosa
Staining of a representative mucosal tissue samples from five normal
controls(N), five Crohndisease(CD), andsix ulcerative colitis (UC) patients
using antibodies against (A) CEACAM1, (B) CSNK1D, and (C) PRKCB1.
(A) CEACAM1 immunoreactivity was found in the apical epithelial lining
(1), crypts of inflamed tissue (2, 4). Additional staining was detected in
immune cells (3) and blood vessels (5).
(B) CSNK1D immunoreactivity showed a strong granular staining pattern
in normal (6) and the UC group (8), which was located basolaterally.
Weaker staining of the apex of the crypts could be detected in CD (7).
(C) For PRKCB1, weak staining could be observed in the apical epithelial
layer in the normal (9) and CD (10) mucosa and, interestingly,
immunoreactivity was found nearly exclusively in the marginal zone of
small lymph follicles (11), whereas the lamina propria was immuno-
negative. In contrast, strong staining was detected in the apical epithelial
layer of UC mucosa (12). Furthermore, lamina propria mononuclear cells
underlying the epithelial layer were also positive in the UC mucosa (13).
DOI: 10.1371/journal.pmed.0020199.g004
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Expression Profiling in IBDCEACAM1 may be a better therapeutic target in CD.
Expression of this adhesion molecule was distributed along
the surface of the normal and IBD mucosa (Figure 4A), but
distribution tended to more deeply penetrate the crypts in
the IBD mucosa. It is tempting to speculate that this ﬁnding
may have a role to play in increasing bacterial load in IBD,
since CEACAM1 can act as a receptor for certain bacteria
[37]. However, association of immunohistochemical ﬁndings
with IBD pathogenesis are strictly speculative, and further
studies, outside the scope of the present study, would need to
be carried out to establish their exact role in disease.
Oncogenesis, Cell Proliferation, and Growth
Within this category, an enrichment of genes associated
with cell growth and proliferation was found for genes up-
regulated in UC (enrichment p ¼ 0.0404; category ‘‘Onco-
genesis, Cell Proliferation, and Growth,’’ Table 3). This
ﬁnding is similar to results from previous microarray studies,
which reported involvement of cancer-related genes in IBD
[11,12], although we report mostly different genes. During
chronic inﬂammation, the constant repair mechanisms
require precise controlling of molecular remodelling, cell
proliferation, and growth [38], and dysregulation of any of
these processes is followed by abnormalities that can lead to
development of cancer [39], which is one of the main long-
term complications of UC. Interestingly, one of the unchar-
acterised transcripts (Chromosome 14 ORF 125/Mm, Rn,
GenBank accession number AL117511; see Table 4) was
assigned as potentially involved in regulation of apoptosis,
which concurs with the above-mentioned studies. Signiﬁcant
up-regulation of cancer-related genes in the UC proﬁle is
potentially important, considering reports of increased risks
of developing colorectal carcinoma in this disease [40,41]. Up-
regulated genes in the UC proﬁle included v-myb myeloblastosis
viral oncogene homolog 2 (MYBL2,Table 3) and several members
of the S100 protein family, whose expression has been
reported to promote cell proliferation and are linked with
increased malignancy or tumour progression in colon cancer
[42–45]. As conﬁrmed by real-time PCR, TFF1 expression was
also markedly higher in the UC group. This ﬁnding may be
very interesting considering earlier studies describing in-
creased TFF1 protein in colorectal cancer [46] and cancer
development in TFF1 knock-out mice [47]. The potentially
speciﬁc role this gene may have in UC is emphasized by the
fact that we ﬁnd no evidence of dysregulation of this gene in
either CD or disease speciﬁcity controls. Similarly, the Wnt
pathway is of intense interest, as aberrant activation is a
common signalling abnormality in human cancers [36,37]. As
members of the casein kinase I (CKI) gene family have been
implicated in the regulation of Wnt-targeted gene expression
[48,49], we used immunohistochemical analysis to localise the
expression of this gene in IBD. Although contrary to the array
results (where this gene was up-regulated in CD but not UC),
the novel immunohistochemical ﬁnding of basolateral stain-
ing of CSNK1D in normal and UC epithelial cells, but only
faint staining in the crypts of CD, may imply a role for Wnt
signalling in IBD pathogenesis. This possibility would need to
be investigated by more in-depth functional studies. The
divergent expression patterns of genes involved in this
category might yet prove useful in understanding the differ-
ent risks of developing colorectal carcinoma between the two
IBD subtypes [50].
Structure and Permeability
Constant tissue damage and injury of the intestinal surface
are part of the pathophysiologic mechanisms in chronic
disorders such as IBD that require continuous repair of the
epithelium [38]. Enhanced permeability for inert macro-
molecules is a well-described clinical feature of CD [51]. Most
interestingly, DLG5, a recently discovered disease gene in
IBD, also appears to be involved in mechanical integrity of
epithelial barriers [7,52,53]. The organic cation transporter
genes SLC22A4 and SLC22A5, which are expressed in
epithelial cells, have also been identiﬁed recently as disease
genes for CD [8]. There is an enrichment of genes associated
with structure and permeability in this study (enrichment p¼
0.0309; category ‘‘Structure and Permeability,’’ Table 3) as
well as in previous microarray studies [11–13]. Several genes
in this category were ubiquitously regulated in both IBD and
non-IBD samples, reﬂecting known gene dysregulation in
disease where inﬂammation and wound healing are recurrent
events. These include paracellular permeability (down-regu-
lation of OCLN) [54], degradation of extracellular matrix (up-
regulation of TIMP and MMP2) [55,56] and barrier protection
against bacterial invasion of the epithelial surface (up-
regulation of MUC1) [57]. Conversely, several genes (LIM
and ROCK) appear speciﬁcally relevant to disease processes in
IBD, as no difference in regulation was observed in inﬂamed
non-IBD patients by real-time PCR. Members of the cadherin
superfamily, integral membrane proteins that mediate
calcium-dependent cell-cell adhesion, have been shown to
be involved in epithelial cell migration and resealing the site
of tissue damage in the intestinal mucosa [58]. In this study,
we show shared up-regulation of cadherin 11 (CDH11) in both
IBD subtypes, too, but not in inﬂamed non-IBD tissue. It is
tempting to speculate that this member of the cadherin
family could also be involved in restructuring processes in the
intestinal mucosa. In the same context, we identiﬁed two
uncharacterised transcripts (GenBank accession numbers
N48794 and AF087994) as differentially regulated, which
were assigned a role in cell-cell adhesion (one of them
containing cadherin repeats).
Cell migration in response to wound healing is regulated in
part by cell adhesion processes, such as Rho-ROCK-mediated
cytoskeletal reorganization [59,60]. Interestingly, members of
this pathway, ROCK1 and LIM, were down-regulated in both
IBD subtypes in our PCR experiments (but not in inﬂamed
DCs), which might indicate a potential decline in cell
migration and an impaired ability to maintain epithelial
integrity in IBD. Furthermore, immunohistochemistry stain-
ing of PRKCB1, which has been shown to interact with LIM
[59], showed that lamina propria cells were preferentially
stained in UC, but not CD or normal controls, possibly
indicating a unique role for this protein in UC. Interestingly,
a genetic variant in DLG5, which was recently associated with
IBD [7], is a PDZ-containing scaffolding protein that
associates with b-catenin and is a binding partner of vinexin
at cell-cell contacts [52]. LIM, in addition to its signalling
function by interacting with PRKCB1 through its LIM domain
[59], also contains PDZ domains, which may be used as sites
for interaction of scaffolding proteins. These ﬁndings might
represent interesting targets for further functional character-
ization in the context of wound healing and regeneration.
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Expression Profiling in IBDThis study represents the largest sample number used in
IBD microarray studies to date and focuses on three groups,
namely normal control, CD, and UC. It would be of interest to
substratify the groups according to other factors, which may
then reveal factor-speciﬁc effects. For example, heterogeneity
in the age distribution of the patient cohort could have the
potential to introduce a bias. To address age-related effects,
an independent analysis omitting age outliers from the
analysis was performed. This did not result in signiﬁcant
changes in the presented list of differentially expressed genes,
with only one out of 650 genes (Zyxin) failing to meet the
cutoff criteria. Similarly, some patients, although meeting
both clinical and endoscopic study inclusion criteria, had no
acute inﬁltrate in their histology assessment (an ‘‘A0’’ score
on histology). The lack of a reliable histological score
reﬂecting disease activity is a well-known phenomenon in
clinical research in IBD [27]. Elimination of individuals with
an ‘‘A0’’ histology score did not change the results in a de
novo analysis. We therefore conclude that the presented
cohort composition was appropriately selected to identify
differentially expressed genes in CD and UC, while noting
that higher numbers of microarray samples would be
necessary to sufﬁciently delineate the effects of additional
clinical parameters. A future agenda would be the assessment
of differential gene expression according to multiple sub-
phenotypes and natural disease course. A prospective cohort
that is adequately powered in size has been assembled and is
currently under investigation.
In conclusion, this study reports our gene ﬁndings using a
large, whole-genome ﬁlter system (Human UniGene set RZPD
1). Our results indicate that there are differences in the gene
expression patterns between normal colonic mucosa and
both CD and UC. The main ﬁndings point to novel,
important molecules in abnormal immune regulation and
the highly disturbed cell biology of the intestine in IBD
pathogenesis. We suggest a host of novel genes that could be
implicated in IBD pathophysiology and pathogenesis. The
large number of involved mechanisms underlines the com-
plexity of the IBD phenotype, but offers a large number of
potential starting points for the development of new
therapeutic strategies in the management of IBD.
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Patient Summary
Background Crohn’s disease and ulcerative colitis are both inflammatory
diseases of the gut, and there is a great deal of overlap between them in
the symptoms that patients have. However, both diseases also have
distinctly different clinical features that allow, in about 80% of patients, a
differentiation between the two diseases. Although some genes have
been shown to be associated with one or the other type of the disease,
the cascade of events that leads to the symptoms we call disease is not
fully understood.
Why Was This Study Done? New technology allows researchers to
compare the function of many thousands of genes side by side. These
researchers wanted to look at how the genes that are expressed (active)
differ between samples taken from the guts of people with these two
conditions.
What Did the Researchers Do and Find? They compared gut samples
from people with inflammatory bowel disease with others taken from
people with normal colon, and others with unrelated colonic diseases.
They found differences in the pattern of expression of hundreds of genes
between Crohn’s disease and ulcerative colitis and samples from other
diseases and normal colonic mucosa. The types of genes mostly altered
were those involved in immunity (how the body protects itself against
outside substances); those involved in mechanisms regulating how cells
multiply (which can go wrong in cancer—one of the complications of
ulcerative colitis) and those that control how the cells of the gut remain
intact.
What Do These Findings Mean? They point to some new areas of
research for these diseases, and possible targets for new drugs. They also
indicate how complex these two diseases are, and suggest that there is
not just one trigger for the diseases.
Where Can I Get More Information Online? National Institute of
Diabetes and Digestive and Kidney Diseases, National Institutes of Health
has an alphabetical list of digestive diseases and links to clinical trials in
this area: http://digestive.niddk.nih.gov/ddiseases/
American and the German Crohn’s and Colitis foundations:
http://www.ccfa.org; http://www.dccv.de
Kompetenznetz—Darmerkrankungen (in German):
http://www.kompetenznetz-ced.de
The researchers’ home page:
http://www.ikmb.uni-kiel.de
PLoS Medicine | www.plosmedicine.org August 2005 | Volume 2 | Issue 8 | e199 0787
Expression Profiling in IBD